Compare Agilent Technologies Inc (A) vs Crispr Therapeutics AG (CRSP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Agilent Technologies Inc vs Crispr Therapeutics AG — how do they compare? Agilent Technologies Inc trades at $149.5 (market cap $42.22B), while Crispr Therapeutics AG trades at $53.96 (market cap $5.23B). The key difference: Agilent Technologies Inc is far larger — about 8.1× Crispr Therapeutics AG's market cap, and Agilent Technologies Inc pays a 0.68% dividend while Crispr Therapeutics AG pays none. Which is the better fit depends on your goals.
| A | CRSP | |
|---|---|---|
Market Cap | $42.22B | $5.23B |
Sector | Health | Health |
52-Week High | $157.20 | $76.78 |
52-Week Low | $110.24 | $44.34 |
Enterprise Value | $43.77B | $3.65B |
Dividend Yield | 0.68% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Agilent Technologies Inc
Originally spun out of Hewlett-Packard in 1999, Agilent has evolved into a leading life sciences and diagnostics firm. Today, Agilent's measurement technologies serve a broad base of customers with its three operating segments: life science and applied tools (45% of fiscal 2021 sales), cross lab (35% of sales consisting of consumables and services related to its life science and applied tools), and diagnostics and genomics (20%). Over half of its sales are generated from the biopharmaceutical, chemical, and energy end markets, but it also supports clinical lab, environmental, forensics, food, academic, and government-related organizations. The company is geographically diverse, with operations in the U.S. (34%) and China (20%) representing the largest country concentrations.
Read more on A →About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →
